ALK-Abelló A/S (0OIR.IL)
| Previous close | 149.45 |
| Open | 93.15 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 92.95 - 93.50 |
| 52-week range | 70.40 - 113.20 |
| Volume | |
| Avg. volume | 58,359 |
| Market cap | 30.001B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 92.83 |
| EPS (TTM) | 1.61 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 Mar 2017 |
| 1y target est | N/A |
GlobeNewswireNine-month interim report (Q3) 2023
ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led by sales of tablets and SCIT. As expected, European tablet sales picked up and grew by 14%, mainly driven by new patient initiations. Operating profit (EBIT) increased by 128% in local currencies on sales growth and gross margin improvements. Q3 2023 financial highlights Comparative figures for Q3 2022 are shown in brackets. Revenue growth rates are stated in local curren
- GlobeNewswire
Release date of nine-month interim report (Q3) 2023 for ALK and audio cast
On Wednesday, 15 November 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its nine-month interim report (Q3) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CET) at which Management will review the financial results, the outlook and answer questions. The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins. To register for the conference call, please use th
- GlobeNewswire
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
The Phase 3 efficacy and safety trial of ALK’s tree tablet involved 952 children aged 5 to 17 in Canada and Europe.ALK has now successfully completed pivotal clinical development for all five respiratory allergy immunotherapy tablets across all relevant age groups. ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced top-line results from a Phase 3 paediatric clinical trial of its sublingual allergy immunotherapy tablet for the treatment of tree-pollen-induced allergic rhinoconjunctivitis. The tre
